All In Biotech

Drug Trial Radar · NCT04790513

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)

Last checked: Nov 20, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

204

Actual

Start

Apr 22, 2021

Primary completion

Sep 30, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
LIB Therapeutics LLCIndustry
Sponsor type
Industry
First posted
Mar 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.

Conditions

  • Hypercholesterolemia
  • Cardiovascular Diseases

Interventions

  • lerodalcibepBiological

    anti-PCSK9 small binding protein

  • evolocumabBiological

    monoclonal antibody to PCSK9

  • alirocumabBiological

    monoclonal antibody to PCSK9

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LDL-C reduction from baseline at 12 weeksTime frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sterling Research Group

    Cincinnati, Ohio

  • The Lindner Research Center

    Cincinnati, Ohio

  • Metabolic & Atherosclerosis Research Center (MARC)

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.